Status:

SUSPENDED

Montelukast for Prevention & Treatment of OHSS

Lead Sponsor:

Benha University

Collaborating Sponsors:

Hawaa Fertility Center

Conditions:

Ovarian Hyperstimulation Syndrome

Eligibility:

FEMALE

20-37 years

Phase:

PHASE2

Brief Summary

montelukast \& dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.

Detailed Description

patients with high risk for ovarian hyperstimulation will undergo a freeze-all protocol then montelukast \& dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one...

Eligibility Criteria

Inclusion

  • PCOS high responders high numbers of ovum retrieved

Exclusion

  • hypersensitivity to any drug components phenylketonuria patients depression liver dysfunction

Key Trial Info

Start Date :

December 5 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2023

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT03794037

Start Date

December 5 2018

End Date

December 1 2023

Last Update

September 21 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Banha University- Hawaa Fertility center

Banhā, Qalyubia Governorate, Egypt, 13512

Montelukast for Prevention & Treatment of OHSS | DecenTrialz